Business
Race Oncology (ASX:RAC) share price slides on a new melanoma preclinical study
The Race Oncology Ltd (ASX: RAC) share price is sliding today, despite the announcement of a new preclinical study by the specialty pharmaceutical company. At the time of writing, shares are down 0.5% to $3.98.
Race Oncology share price unfazed by Bisantrene study
Race Oncology focuses on the development of cancer-targeting drugs in an effort towards better outcomes. The company’s flagship drug is Bisantrene, a small molecule inhibitor of the fat mass and obesity-associated (FTO) protein. A link between FTO and a range of cancers has led Race to investigate Bisantrene further.
According to the release, Race has now entered…
-
Noosa News11 hours agoFormer NRL player Teui ‘TC’ Robati lured woman to pub toilet before alleged rape, jury told
-
Noosa News19 hours agoCattle claimants ‘bitterly disappointed’ after court downplays compensation claim from live export ban
-
General12 hours agoIran expands dog-walking ban, citing ‘public health, peace and comfort’ concerns
-
General23 hours agoInquest to be held into Gladstone woman Courtney Anderson’s death